Assorted News from the Last Week:
CAC2 Member Blog from Stan Robbins–Awareness & Entertainment Opportunity: Audrey’s Children Childhood cancer survivors have a more than two-fold increased risk of developing melanoma during their lifetime, compared to the general population, as well as a two-fold increased risk of death associated with a melanoma diagnosis. Suicidal ideation significantly higher among childhood cancer survivors. Newborns with heart defects may face a higher risk of developing childhood cancer. New therapeutic approach shows promise for pediatric high-grade gliomas. New NCI Pediatric Preclinical In Vivo Testing Consortium (PIVOT) study data are in the CCDI Data Ecosystem. The data are from molecular testing results from pediatric acute lymphoblastic leukemia (ALL) and neuroblastoma patient-derived xenograft (PDX) models. Included are data from next-generation sequencing and whole-genome chromosome analysis. Blinatumomab boosts chemotherapy as initial treatment for some kids with ALL. Upcoming Webinars, Online Opportunities, and Meetings:Recent Recordings:
Global Platform for Access to Childhood Cancer Medicines. January CCDI webinar, “Unlock the Power of Unstructured Data with EMERSE,” is now availableTake Action:
CAC2 Innovation Council Recommendation: ARYA-2 Clinical Trial for Pediatric Liver Cancer
Overview of the Opportunity: This request concerns a Phase 1/2 clinical trial, evaluating ET140203 T Cells in pediatric patients with relapsed/refractory Hepatoblastoma, Hepatocellular Neoplasm-Not Otherwise Specified, or Hepatocellular Carcinoma.
The Requester: Nicole Nunez, Associate Director of Patient Engagement and Regulatory Affairs (PhD), Eureka Therapeutics, Inc.
The Type of Request: Information sharing about a clinical trial opportunity for children with liver cancer. Sharing information about a trial does not imply that CAC2 is recommending or endorsing. Each patient should check with their medical professionals.
The Ask: Inform CAC2 Members about the ARYA-2 clinical trial (NCT04634357) which is a multi-center, Phase 1/2 clinical trial currently in the dose escalation phase, evaluating ET140203 T Cells in pediatric patients with relapsed/refractory Hepatoblastoma, Hepatocellular Neoplasm-Not Otherwise Specified, or Hepatocellular Carcinoma.
Please share the clinical trial flyer and help connect the trial team with any entities that can help bring awareness about this trial. Since pediatric liver cancer is an ultra rare disease (less than 200 kids diagnosed every year in the US), the trial team is doing everything it can to let doctors, patients and patient community groups know that this trial is open and actively recruiting.
Supporting Documentation: The trial is currently open at Dana-Farber Boston Children’s Cancer Institute, UCSF Benioff Children’s Hospitals, and Children’s Hospital Los Angeles. Autologous ET140203 T-cell therapy is designed to specifically target and destroy AFP/HLA-A2-positive liver cancer, while minimizing potential side effects traditionally associated with cancer treatment.
Eureka Therapeutics provides financial support for the patient and one caregiver to cover travel, food and accommodations during their participation in the trial.
Informational Flyer: https://drive.google.com/file/d/1fYAQL-yBVbzV4lv4xrKYEUQUmin7GR0R/view?usp=share_link
Patient friendly website at: www.eurekaconnectme.com
Corporate website is: www.eurekatherapeutics.com
For more information on the clinical trial, including details regarding eligibility criteria, please visit the clinicaltrials.gov website page: https://clinicaltrials.gov/study/NCT04634357
